Rexahn pharmaceuticals, inc. (REXN)
CashFlow / Quarterly
Mar'20Dec'19Sep'19Jun'19Mar'19Dec'18Sep'18Jun'18Mar'18Dec'17Sep'17Jun'17Mar'17Dec'16Sep'16Jun'16Mar'16Dec'15Sep'15Jun'15Mar'15Dec'14Sep'14Jun'14Mar'14Mar'12Dec'11Sep'11Jun'11Mar'11
Cash Flows from Operating Activities:
Net loss

-586

-1,868

-1,959

-2,464

-2,342

-3,116

-5,338

-3,838

-2,074

-3,592

-1,038

947

-21,611

-525

-2,866

-1,765

-4,149

-2,852

-4,026

-3,234

-4,271

-2,210

-1,905

194

-14,600

-2,139

389

-1,469

-5,828

-4,436

Adjustments to reconcile net loss to net cash used in operating activities:
Beneficial conversion feature

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

0

0

0

Compensatory stock

-

-

-

-

-

0

10

0

12

0

18

0

12

0

32

16

48

0

45

0

56

0

73

0

336

0

0

0

0

0

Depreciation and amortization

9

9

9

10

11

11

10

12

14

11

11

11

8

8

9

8

6

7

7

6

6

5

3

9

9

10

10

10

10

14

Loss on sale of equipment

-

0

0

0

-9

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Amortization of premiums and discounts on marketable securities, net

4

21

30

37

18

-4

-8

-11

-14

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Amortization of premiums and discounts on marketable securities, net

-

-

-

-

-

-

-

-

-

-

20

14

5

0

-0

9

13

9

7

7

6

-

-

-

-

-

-

-

-

-

Stock-based compensation

76

77

90

127

161

383

281

267

296

254

227

288

274

345

369

351

343

268

225

271

272

184

163

132

128

91

125

141

170

201

Amortization and termination of deferred research and development arrangement

-

-

-

-

-

0

0

0

-375

-18

-18

-18

-18

-18

-18

-18

-18

-18

-18

-18

-18

-18

-59

-104

-51

-18

-

-

-

-18

Unrealized loss (gain) on fair value of warrants

58

-82

-242

-427

-1,513

-1,793

710

-1,095

-3,366

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Unrealized (gain) loss on fair value of warrants

-

-

-

-

-

-

-

-

-

-

3,120

5,521

-17,689

1,588

967

2,118

855

-

-

-

-

-

-

-

-

-

-

-

-

-

Note receivable (Note 5)

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

7

7

7

7

7

Realized losses on marketable securities

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

0

-3

0

Unrealized (gain) loss on fair value of warrants

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-115

-

-1,201

-3,665

11,660

261

-2,784

-1,866

-594

467

Unrealized gain on fair value of put feature on common stock

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

0

0

0

Financing expense

-

-

-

-

-

-

-

-

-

-

-

-

-

0

143

0

169

-

-

-

-

0

0

0

206

0

0

0

0

97

Amortization of deferred lease incentive

-

-

-

-

-

-

-3

-3

-3

-3

-3

-3

-3

-3

-3

-3

-3

-3

-3

-3

-3

-3

-3

-3

-3

-5

-5

-5

-5

-5

Deferred rent

-

-

-

-

-

-

-6

-5

-5

-1

-1

-3

-3

-3

-3

-2

-2

-2

-2

-1

-1

-1

-1

-0

11

4

4

4

0

0

Loss on impairment of intangible assets

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

0

0

0

Changes in assets and liabilities:
Prepaid expenses and other assets

-156

-275

-310

51

-73

-81

-210

134

-73

26

77

234

356

-193

-194

50

-275

-253

198

291

260

-0

-143

175

218

-45

-122

-30

-239

18

Research tax credit receivable

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

0

0

145

Accounts payable and accrued expenses

-28

-100

-554

-325

-906

-179

-50

332

-184

895

534

88

-167

96

-8

-1,489

622

-576

69

419

290

733

185

661

-55

-165

-2,720

13

951

1,118

Deferred revenue

-900

0

0

1,350

150

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Other, net

1

1

1

-11

4

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Net Cash Used in Operating Activities

-1,221

-1,712

-2,377

-1,806

-4,380

-4,620

-4,167

-4,453

-5,598

-3,704

-3,447

-4,099

-4,168

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Net Cash Used in Operating Activities

-

-

-

-

-

-

-

-

-

-

-

-

-

-1,493

-3,121

-5,062

-3,549

-4,407

-4,502

-4,402

-4,038

-2,911

-2,601

-2,951

-2,576

-1,916

-4,878

-3,161

-5,064

-2,425

Cash Flows from Investing Activities:
Restricted cash equivalents

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-37

-40

-85

-32

-156

-1,515

-230

-181

2,957

Purchase of equipment

-

0

0

6

13

0

35

0

2

53

3

13

3

0

0

2

4

9

40

4

7

11

15

10

3

0

11

2

2

0

Sale of equipment

-

0

0

0

5

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Purchase of marketable securities

-

0

0

0

8,887

-

-

-

-

6,008

0

13,002

2,005

0

7,025

0

1,721

7,167

0

0

740

-

-

-

-

0

0

0

8,000

0

Redemption of marketable securities

3,000

3,000

3,000

3,000

3,000

2,000

3,700

3,250

3,000

3,000

3,000

3,000

2,720

4,680

5,120

2,480

960

2,900

7,000

2,640

4,985

-

-

-

-

0

0

0

8,500

0

Net Cash (Used in) Provided by Investing Activities

-

-

-

-

-

-

-

-

-

-

-

-

-

4,679

-1,906

2,477

-766

-4,277

6,959

2,635

4,236

-2,233

-20,531

74

28

-

-

-

-

-

Payment of licensing fees

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

0

0

0

Net Cash Provided by (Used in) Investing Activities

3,000

3,000

3,000

2,993

-5,895

2,000

3,664

3,249

2,997

-3,062

2,996

-10,016

710

-

-

-

-

-

-

-

-

-

-

-

-

156

1,504

228

679

-2,957

Cash Flows from Financing Activities:
Issuance of common stock and units, net of issuance costs

-

0

0

0

7,653

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Issuance of common stock and units, net of issuance costs

-

-

-

-

-

-

-

-

-

-

-

-

-

0

5,542

0

4,580

-

-

-

-

0

0

0

18,634

0

0

0

0

13,220

Proceeds from exercise of stock warrants

-

-

-

-

-

-

-

-

-

0

0

2,987

2,366

-

-

-

-

-

-

-

-

0

0

718

5,228

-

-

-

-

-

Proceeds from exercise of stock options

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

3

705

0

0

188

70

0

19

22

0

18

Net Cash Provided by Financing Activities

-

-

-

-

-

-

-

-

-

-

-

-

-

0

5,542

0

4,580

6,434

22

1,008

705

0

0

907

23,932

-

-

-

-

-

Proceeds from exercise of stock warrants

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

0

0

317

Proceeds from long-term debt

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

0

0

0

Proceeds from research and development arrangement

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

0

0

0

Purchase of treasury stock

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

0

0

0

Net Cash Provided by Financing Activities

-

0

0

0

7,653

-

-

-

-

7,440

-113

12,420

2,366

-

-

-

-

-

-

-

-

-

-

-

-

0

19

22

0

13,556

Net Increase (Decrease) in Cash and Cash Equivalents

1,778

1,287

622

1,187

-2,621

4,152

-502

-1,204

-2,600

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Net Decrease in Cash and Cash Equivalents

-

-

-

-

-

-

-

-

-

672

-564

-1,695

-1,092

3,186

514

-2,585

264

-2,250

2,479

-758

902

-5,145

-23,132

-1,968

21,384

-1,760

-3,355

-2,910

-4,385

8,172

Supplemental Cash Flow Information
Operating cash flows paid for amounts included in the measurement of lease liabilities

38

38

38

36

84

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Interest paid

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

0

0

0

Non-cash financing and investing activties:
Warrants issued

-

0

0

0

4,735

-

-

-

-

-

-

-

-

0

1,788

0

2,575

-

-

-

-

0

0

0

3,691

0

0

0

0

2,924

Operating lease right-of-use assets obtained in exchange for lease obligations:

-

0

0

0

380

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Warrant liability extinguishment from exercise of warrants

-

-

-

-

-

-

-

-

-

0

0

5,023

3,029

-

-

-

-

-

-

-

-

0

0

1,041

9,095

-

-

-

-

-

Stock subscription receivable from warrants exercised

-

-

-

-

-

-

-

-

-

-

-

-

30

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Put feature on common stock issued

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

0

0

0

Dilutive issuances of common stock

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

0

0

0

Warrant liability extinguishment from exercise of warrants

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

0

0

243

Leasehold improvement incentive

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

0

0

0

Settlement of lawsuit

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

0

0

0